Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans

Clinical Pharmacology and Therapeutics

Volumn 61, Issue 6, 1997, Pages 619-627

  Becquemont, Laurent ^a   Ragueneau, Isabelle ^b   Le Bot, Marie Annick ^b   Riche, Christian ^b   Funck Brentano, Christian ^b   Jaillon, Patrice ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; FLUVOXAMINE; FLUVOXAMINE MALEATE; TACRINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG INTERACTION; DRUG METABOLISM; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; LIVER TOXICITY; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AREA UNDER CURVE; CHOLINESTERASE INHIBITORS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP1A2; DOUBLE-BLIND METHOD; FLUVOXAMINE; HUMANS; MALE; REFERENCE VALUES; REGRESSION ANALYSIS; SEROTONIN UPTAKE INHIBITORS; TACRINE;

EID: 0030977293     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90095-3     Document Type: Article

References (24)

1. Knapp MJ, Knopman DS, Solomon PR, Pendlelbury W, Davis, CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-91.
2. Schneider LS. Clinical pharmacology of aminoacridines in Alzheimer's disease. Neurology 1993; 43(suppl 4):S64-79.
3. Walkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271:992-8.
4. Fariss MW, Johnsen SA, Walton LP, Mumaw VR, Ray SD. Tetrahydroaminoacridine-induced ribosomal changes and inhibition of protein synthesis in rat hepatocyte suspension. Hepatology 1994;20: 240-6.
5. Madden S, Woolf TF, Pool WF, Park BK. An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Biochem Pharmacol 1993;46:13-20.
6. Madden S, Spaldin V, Hayes RN, Woolf TF, Pool WF, Park BK. Species variation in bioactivation of tacrine by hepatic microsomes. Xenobiotica 1995;25: 103-16.
7. Woolf TF, Pool WF, Bjorge M, Chang T, Goel OP, Purchase CF II, et al. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Drug Metab Dispos 1993;21:874-82.
8. Spaldin V, Madden S, Pool WF, Woolf TF, Park BK. The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes. Br J Clin Pharmacol 1994;38:15-22.
9. Becquemont L, Le Bot MA, Riche C, Beaune P. Influence of fluvoxamine on tacrine metabolism in vitro: potential implication for the hepatotoxicity in vivo. Fundam Clin Pharmacol 1996;10:156-7.
10. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P450 1A2. Biochem Pharmacol 1993;45:1211-4.
11. Sperber AD. Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Safety 1991;6:460-2.
12. Davis KL, Powchik P. Tacrine. Lancet 1995;345:625-30.
13. Haughey DB, McNaney CA, Collis MS, Brown RR, Siedlik PH, Balogh L, et al. Simultaneous determination of tacrine and 1-hydroxy-, 2-hydroxy-, and 4-hydroxytacrine in human plasma by high-performance liquid chromatography with fluorescence detection. J Pharm Sci 1994;83:1582-5.
14. Foglia JP, Birder LA, Perel JM. Determination of fluvoxamine in human plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr 1989;495:295-302.
15. Chiou WL. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level time curve. J Pharmacokinet Biopharm 1978;6:539-46.
16. Hooper WD, Pool WF, Woolf TF, Gal J. Stereoselective hydroxylation of tacrine in rats and humans. Drug Metab Dispos 1994;22:719-24.
17. Spaldin V, Madden S, Adams DA, Edwards RJ, Davies DS, Park BK. Determination of human hepatic cytochrome P4501A2 activity in vitro: use of tacrine as an isoenzyme-specific probe Drug Metab Dispos 1995;23:929-34.
18. Selen A, Balogh L, Siedlik P. Pharmacokinetics of tacrine in healthy subjects [abstract]. Pharm Res 1988; 5:S218.
19. Hartvig P, Askmark H, Aquilonius SM, Wiklund L, Lindström B. Clinical pharmacokinetics of intravenous and oral 9-amino-1,2,3,4-tetrahydroacridine, tacrine. Eur J Clin Pharmacol 1990;38:259-63.
20. Cutler NR, Sedman AJ, Prior P, Underwood BA, Selen A, Balogh L, et al. Steady-state pharmacokinetics of tacrine in patients with Alzheimer's disease. Psychopharmacol Bull 1990;26:231-4.
21. Belloc C, Baird S, Cosme J, Lecoeur S, Gautier JC, Challine D, et al. Human cytochromes P450 expressed in Escherichia coli: production of specific antibodies. Toxicology 1996;106:207-19.
22. Fuhr U, Anders EM, Mahr G, Sörgel F, Staib AH. Inhibitory potency of quinolone antibacterial agents against cytochrome P4501A2 activity in vivo and in vitro. Antimicrob Agents Chemother 1992;36:942-8.
23. Fuhr U, Klittich K, Staib AH. Inhibitory effect of grapefruit juice and its bitter principal naringenin, on CYP1A2 dependent metabolism in man. Br J Clin Pharmacol 1993;35:431-6.
24. Knodell RG, Browne DG, Gwozdz GP, Brian WR, Guengerich FP. Differential inhibition of individual human liver cytochromes P-450 by cimetidine. Gastroenterology 1991;101:1680-91.